Phase 1/2a Trial to Evaluate the Safety, Tolerability and Efficacy of Nebulised RESP30X Nitric Oxide Formulations in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients with Pseudomonas Aeruginosa (Pa) or other Potentially Pathogenic Micro-organisms (PPMs).

Non-Cystic Fibrosis Bronchiectasis with Pseudomonas Aeruginosa or other Potentially Pathogenic Micro-organisms

1. Incidence, intensity, causality, and seriousness of treatment-emergent adverse events (TEAEs)., 2. Changes in clinical laboratory values (haematology, clinical chemistry) at each time point., 3. Changes in vital signs (blood pressure, heart rate, temperature, respiratory rate) and oxygen saturation (SpO2) at each time point.

Plasma PK parameters peak serum concentration (Cmax), time to peak serum concentration (Tmax), area under the concentration-time curve from dosing (time 0) to time t (AUC0-t), area under the concentration-time curve from dosing (time 0) to end of dosing period (AUC0-tau), area under the concentration-time curve for total drug exposure from dosing (time 0) extrapolated to infinity (AUC0-inf), trough plasma concentration (Ctrough), and half-life (t1/2).

No related papers found yet.

Bulgaria, Poland, Romania